A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 01 Nov 2016 Results published in the American Journal of Gastroenterology
    • 22 May 2012 Results presented at Digestive Disease Week 2012.
    • 22 Sep 2011 Planned end date changed from 1 Mar 2012 to 1 Aug 2011 as reported by ClinicalTrials.gov (NCT01150890).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top